Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase.

Clinical and translational science - 1 May 2022

Kang Jihyun, Kim Andrew HyoungJin, Jeon Inseung, Oh Jaeseong, Jang In-Jin, Lee SeungHwan, Cho Joo-Youn

Abstract excerpt

Five-fluorouracil (5-FU) is a chemotherapeutic agent that is mainly metabolized by the rate-limiting enzyme dihydropyrimidine dehydrogenase (DPD). The DPD enzyme activity deficiency involves a wide range of severities. Previous studies have demonstrated the effect of a DPYD single nucleotide polymorphism on 5-FU efficacy and highlighted the importance of studying such genes for cancer treatment. Common...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dihydrouracil Dehydrogenase (NADP)
Share to Fluorouracil

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polymorphism, Single Nucleotide

Share to Uridine

Source

Open in PubMed Open full text

Identifiers

PMID: 34863048
DOI: 10.1111/cts.13203
PMCID: PMC9099117

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase.PMID 34863048Read ↗

Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients.Semantic proximity Read ↗

Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?Semantic proximity Read ↗

Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio.Semantic proximity Read ↗

Identification of DPYD variants and estimation of uracil and dihydrouracil in a healthy Indian population.Semantic proximity Read ↗

An optimized HPLC-MS/MS assay for uracil and dihydrouracil in plasma: Improving dihydropyrimidine dehydrogenase phenotyping for individualized fluoropyrimidine treatment.Semantic proximity Read ↗

Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.Semantic proximity Read ↗

Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.Semantic proximity Read ↗

Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population.Semantic proximity Read ↗

Implications of Dihydropyrimidine Dehydrogenase on 5-Fluorouracil Pharmacogenetics and PharmacogenomicsSemantic proximity Read ↗

DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview.Semantic proximity Read ↗

A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency.Semantic proximity Read ↗

[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.